Document is current
Any future updates will be listed below
-
Authors
Mages, Simon https://orcid.org/0000-0003-1447-6811
Moriel, Noa
Avraham-Davidi, Inbal https://orcid.org/0000-0001-7118-9179
Murray, Evan
Watter, Jan https://orcid.org/0000-0001-7519-731X
Chen, Fei https://orcid.org/0000-0003-2308-3649
Rozenblatt-Rosen, Orit https://orcid.org/0000-0001-6313-3570
Klughammer, Johanna https://orcid.org/0000-0002-3628-9278
Regev, Aviv https://orcid.org/0000-0003-3293-3158
Nitzan, Mor https://orcid.org/0000-0003-0074-9196
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (MA 9108/1-1)
Center for Interdisciplinary Data Science Research at the Hebrew University of Jerusalem
Human Frontier Science Program (LT000452/2019-L)
U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (5RM1HG006193-09)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (1U24 CA180922)
U.S. Department of Health & Human Services | NIH | Office of Extramural Research, National Institutes of Health (1U19 MH114821)
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (1RC2 DK114784)
Howard Hughes Medical Institute
Klarman Cell Observatory MIT Ludwig Center Manton Family Foundation
Israel Science Foundation (1079/21)
Azrieli Foundation
Google
Center for Interdisciplinary Data Science Research at the Hebrew University of Jerusalem Horizon Europe ERC Grant
- License Information
-
More Information
Article History
Received: 15 June 2022
Accepted: 2 January 2023
First Online: 16 February 2023
Competing interests
: A.R. is a cofounder and equity holder of Celsius Therapeutics, an equity holder in Immunitas, and was a SAB member of ThermoFisher Scientific, Syros Pharmaceuticals, Neogene Therapeutics and Asimov until 31 July 2020. From 1 August 2020, A.R. is an employee of Genentech and has equity in Roche. F.C. is a founder and holds equity in Curio Biosciences. A.R. and O.R.-R. are co-inventors on patent applications filed by the Broad Institute for inventions related to single-cell genomics. O.R.-R. has given numerous lectures on the subject of single-cell genomics to a wide variety of audiences, and in some cases, she has received remuneration to cover time and costs. O.R.-R. is an employee of Genentech since October 19, 2020, and has equity in Roche. The remaining authors declare no competing interests.
